Ontario

Ministry of Health
Drugs and Devices Division

Executive Officer Notice: Regulation Amendments to Private Label Products and Brand Reference Pricing Rules

April 7, 2020

The purpose of this notice is to provide you with information regarding recent amendments to Ontario Regulation 201/96 under the *Ontario Drug Benefit Act* (ODBA) and Regulation 935 under the *Drug Interchangeability and Dispensing Fee Act* (DIDFA). These amendments:

- changed the effective date of previously announced regulatory amendments that allow private label products (PLPs) to be designated as listed drug products under the ODBA and as interchangeable products under DIDFA from July 1st, 2020 to April 1st, 2020; and
- provide the Executive Officer with the authority to align Ontario's rules for setting brand reference prices with the national approach used by the pan-Canadian Pharmaceutical Alliance (pCPA).

The amendments have been approved by the Ontario Government and have a retroactive effective date of April 1, 2020.

These amendments were made to provide greater stability to Ontario's drug supply, especially in light of the COVID-19 outbreak.

For the authoritative text of the regulations, please visit the e-Laws website at: http://www.ontario.ca/laws

Questions regarding the regulations can be directed to:

Drugs and Devices Division
Ministry of Health
5700 Yonge Street, 3rd Floor
Toronto ON
M2M 4K5
Fax: 416-325-6647
E-mail: PublicDrugPrgrms.moh@ontario.ca